Harvard Bioscience

HBIO52

Penny Stock

$2.71arrow_drop_down0.73%-$0.02

Penny Stock

HBIO52

$2.71

arrow_drop_down0.73%-$0.02

Penny Stock

Performance History

Key Stats
Open	$2.71
Prev. Close	$2.73
EPS	-0.25
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$119.92M
PE Ratio	-

	LOW	HIGH
Day Range	2.65	2.75
52 Week Range	2.61	5.56

Ratios







EPS	-0.25

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Harvard Bioscience (HBIO)

Harvard Bioscience Inc, also known as HBIO, is a life sciences company that designs, manufactures, and markets scientific instruments. The company offers a wide range of products, including laboratory equipment, consumables, and systems for drug discovery and research. HBIO's products are used by researchers and scientists in universities, government laboratories, and pharmaceutical and biotech companies around the world. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

HBIO's stock price history shows a fluctuating trend over the years. The stock has experienced both highs and lows, with significant volatility in certain periods. In recent news, HBIO announced the acquisition of a leading manufacturer of laboratory instruments, expanding its product portfolio and enhancing its market position. This strategic move is expected to drive future growth for the company.

Websitecall_made

Sector: Healthcare
Industry: Medical Instruments & Supplies
CEO: Mr. James W. Green
Headquarters: Holliston
Employees: 436
Exchange: NASDAQ

Keep an eye on Harvard Bioscience

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Harvard Bioscience (HBIO)?

Harvard Bioscience (HBIO) has a market capitalization of $119.93M. The average daily trading volume is 111.28K, indicating the stock's liquidity and investor engagement.

help

What is Harvard Bioscience 's (HBIO) price per share?

The current price per share for Harvard Bioscience (HBIO) is $2.71. The stock has seen a price change of -$0.02 recently, indicating a -0.73% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Harvard Bioscience (HBIO)?

For Harvard Bioscience (HBIO), the 52-week high is $5.56, which is 105.17% from the current price. The 52-week low is $2.61, the current price is 3.83% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Harvard Bioscience (HBIO) a growth stock?

Harvard Bioscience (HBIO) has shown an average price growth of 0.41% over the past three years. It has received a score of 28 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Harvard Bioscience as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Harvard Bioscience (HBIO) stock price performance year to date (YTD)?

As of the latest data, Harvard Bioscience (HBIO) has a year-to-date price change of -49.72%. Over the past month, the stock has experienced a price change of -6.87%. Over the last three months, the change has been -9.06%. Over the past six months, the figure is -34.06%. Looking at a longer horizon, the five-year price change stands at 8.84%.

help

Is Harvard Bioscience (HBIO) a profitable company?

Harvard Bioscience (HBIO) has a net income of -$3.42M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 54.22% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -7.24% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $112.25M, although specific revenue growth data is currently not available. The gross profit is $60.87M. Operating income is noted at $2.28M. Furthermore, the EBITDA is $8.66M.